Cardio3 Biosciences Seeking $32M in European IPO Market
Cardio3 Biosciences SA is the third European biotechnology company to dip its toes in the initial public offering (IPO) waters this year. The Belgian stem cell therapy developer is seeking up to €24.7 million (US$32.5 million) in an offering on the NYSE Euronext Exchanges in Brussels and Paris.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter